Research Paper Volume 15, Issue 7 pp 2734—2771

Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma


Figure 2. TSEN54 expression is associated with multiple clinicopathological features. Box-whisker plots reveal the variability of gene expression level ground on subgroup (A) tumor grade; (B) individual cancer stages; (C) patient’s race; (D) patient’s gender; (E) TP53 mutation status; (F) histological subtypes. The relationship between TSEN54 expression and (G) grade; (H) stage; (I) T stage in HCC according to data from the TCGA database. (*, p < 0.05; **, p < 0.01; ***, p < 0.001).